Literature DB >> 19505976

The prescribing of specialist medicines: what factors influence GPs' decision making?

Sarah Crowe1, Mary P Tully, Judith A Cantrill.   

Abstract

BACKGROUND: As Governments worldwide strive to integrate efficient health care delivery across the primary-secondary care divide, particular significance has been placed on the need to understand GPs' prescribing of specialist drugs.
OBJECTIVE: To explore the factors which influence GPs' decision-making process when requested to prescribe specialist drugs.
METHODS: A qualitative approach was used to explore the perspectives of a wide range of practice-, primary care trust-, strategic health authority-level staff and other relevant stakeholders in the North-West of England. All semi-structured interviews (n = 47) were analysed comprehensively using the five-stage 'framework' approach.
RESULTS: Six diverse factors were identified as having a crucial bearing on how GPs evaluate initial requests and subsequently decide whether or not to prescribe. These include GPs' lack of knowledge and expertise in using specialist drugs, the shared care arrangement, the influence of a locally agreed advisory list, financial and resource considerations, patient convenience and understanding and GPs' specific areas of interest.
CONCLUSION: This exploration of GPs' decision-making process is needed to support future integrated health care delivery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19505976     DOI: 10.1093/fampra/cmp030

Source DB:  PubMed          Journal:  Fam Pract        ISSN: 0263-2136            Impact factor:   2.267


  10 in total

1.  Improving specialist drug prescribing in primary care using task and error analysis: an observational study.

Authors:  Narinder Chana; Talya Porat; Cate Whittlesea; Brendan Delaney
Journal:  Br J Gen Pract       Date:  2017-02-13       Impact factor: 5.386

2.  Antibiotics without Prescriptions: US & Indian Perspective.

Authors:  Nancy Khardori; Chand Wattal
Journal:  Indian J Pediatr       Date:  2019-12-06       Impact factor: 1.967

3.  Why shared-care arrangements for prescribing in attention deficit hyperactivity disorder may not be accepted.

Authors:  I M Carrington; J McAloon
Journal:  Eur J Hosp Pharm       Date:  2015-10-13

4.  An ethnographic exploration of influences on prescribing in general practice: why is there variation in prescribing practices?

Authors:  Aileen Grant; Frank Sullivan; Jon Dowell
Journal:  Implement Sci       Date:  2013-06-21       Impact factor: 7.327

Review 5.  Systematic literature review of pharmacists in general practice in supporting the implementation of shared care agreements in primary care.

Authors:  Naveed Iqbal; Chi Huynh; Ian Maidment
Journal:  Syst Rev       Date:  2022-05-11

6.  Evaluation of antibiotic prescriptions and use in under-five children in Ibadan, SouthWestern Nigeria.

Authors:  Rasaq Adisa; Ochuko M Orherhe; Titilayo O Fakeye
Journal:  Afr Health Sci       Date:  2018-12       Impact factor: 0.927

7.  Young people with attention deficit hyperactivity disorder in transition from child to adult services: a qualitative study of the experiences of general practitioners in the UK.

Authors:  Tamsin Newlove-Delgado; Sharon Blake; Tamsin Ford; Astrid Janssens
Journal:  BMC Fam Pract       Date:  2019-11-20       Impact factor: 2.497

8.  Unlicensed medicines use: a UK guideline analysis using AGREE II.

Authors:  Gemma Donovan; Lindsay Parkin; Lyn Brierley-Jones; Scott Wilkes
Journal:  Int J Pharm Pract       Date:  2018-01-30

9.  Factors Influencing Prescribing Decisions of Physicians: A Review.

Authors:  Majid Davari; Elahe Khorasani; Bereket Molla Tigabu
Journal:  Ethiop J Health Sci       Date:  2018-11

10.  Provider-related barriers and enablers to the provision of hepatitis C treatment by general practitioners in Scotland: A behaviour change analysis.

Authors:  David Whiteley; Elizabeth Speakman; Lawrie Elliott; Katherine Davidson; Emma Hamilton; Helen Jarvis; Michael Quinn; Paul Flowers
Journal:  J Viral Hepat       Date:  2020-12-07       Impact factor: 3.728

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.